[HTML][HTML] Alternative molecular formats and therapeutic applications for bispecific antibodies
C Spiess, Q Zhai, PJ Carter - Molecular immunology, 2015 - Elsevier
Bispecific antibodies are on the cusp of coming of age as therapeutics more than half a
century after they were first described. Two bispecific antibodies, catumaxomab (Removab® …
century after they were first described. Two bispecific antibodies, catumaxomab (Removab® …
Antibody responses to viral infections: a structural perspective across three different enveloped viruses
CD Murin, IA Wilson, AB Ward - Nature microbiology, 2019 - nature.com
Antibodies serve as critical barriers to viral infection. Humoral immunity to a virus is achieved
through the dual role of antibodies in communicating the presence of invading pathogens in …
through the dual role of antibodies in communicating the presence of invading pathogens in …
Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp
Without an approved vaccine or treatments, Ebola outbreak management has been limited
to palliative care and barrier methods to prevent transmission. These approaches, however …
to palliative care and barrier methods to prevent transmission. These approaches, however …
Host-directed therapies for infectious diseases: current status, recent progress, and future prospects
Despite extensive global efforts in the fight against killer infectious diseases, they still cause
one in four deaths worldwide and are important causes of long-term functional disability …
one in four deaths worldwide and are important causes of long-term functional disability …
Ebola virus infection: review of the pharmacokinetic and pharmacodynamic properties of drugs considered for testing in human efficacy trials
V Madelain, THT Nguyen, A Olivo… - Clinical …, 2016 - Springer
The 2014–2015 outbreak of Ebola virus disease is the largest epidemic to date in terms of
the number of cases, deaths, and affected areas. In October 2015, no antiviral agents had …
the number of cases, deaths, and affected areas. In October 2015, no antiviral agents had …
[HTML][HTML] The role of Fc–FcγR interactions in IgG-mediated microbial neutralization
Antibodies are bifunctional molecules, containing a variable Fab domain that mediates
binding specificity and a constant Fc domain that bridges antibody-coated targets with FcγR …
binding specificity and a constant Fc domain that bridges antibody-coated targets with FcγR …
Fcγ receptor pathways during active and passive immunization
S Bournazos, JV Ravetch - Immunological reviews, 2015 - Wiley Online Library
IgG antibodies are actively produced in response to antigenic challenge or passively
administered as an effective form of immunotherapy to confer immunity against foreign …
administered as an effective form of immunotherapy to confer immunity against foreign …
Mechanism of binding to Ebola virus glycoprotein by the ZMapp, ZMAb, and MB-003 cocktail antibodies
E Davidson, C Bryan, RH Fong, T Barnes… - Journal of …, 2015 - Am Soc Microbiol
Cocktails of monoclonal antibodies (MAbs) that target the surface glycoprotein (GP) of Ebola
virus (EBOV) are effective in nonhuman primate models and have been used under …
virus (EBOV) are effective in nonhuman primate models and have been used under …
Development of a human antibody cocktail that deploys multiple functions to confer pan-ebolavirus protection
Passive administration of monoclonal antibodies (mAbs) is a promising therapeutic
approach for Ebola virus disease (EVD). However, all mAbs and mAb cocktails that have …
approach for Ebola virus disease (EVD). However, all mAbs and mAb cocktails that have …
Structures of Ebola virus GP and sGP in complex with therapeutic antibodies
Abstract The Ebola virus (EBOV) GP gene encodes two glycoproteins. The major product is
a soluble, dimeric glycoprotein (sGP) that is secreted abundantly. Despite the abundance of …
a soluble, dimeric glycoprotein (sGP) that is secreted abundantly. Despite the abundance of …